Poewe W, Stankovic I, Halliday G, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma J-A, Kaufmann H. Multiple system atrophy. Nat Rev Dis Primers. 2022;8:1–21.

Google Scholar 

Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293–309.

PubMed  PubMed Central  Google Scholar 

Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. The Lancet Neurology. 2013;12:264–74.

PubMed  PubMed Central  Google Scholar 

Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM-Y. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in non-transgenic mice. Science. 2012;338:949–53.

ADS  CAS  PubMed  PubMed Central  Google Scholar 

Wong YC, Krainc D. α-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1–13.

CAS  PubMed  PubMed Central  Google Scholar 

Inoue M, Yagishita S, Ryo M, Hasegawa K, Amano N, Matsushita M. The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol. 1997;93:585–91.

CAS  PubMed  Google Scholar 

Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127:2657–71.

PubMed  Google Scholar 

Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature. 2018;557:558–63.

ADS  CAS  PubMed  PubMed Central  Google Scholar 

• Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578:273–7. This article explores the accuracy of a seed amplification assay to detect different patterns of alpha-synuclein aggregation between MSA and PD patients. They combined different methods to compare these patterns and observed distinct conformational strains of alpha-synuclein between MSA and PD

ADS  CAS  PubMed  PubMed Central  Google Scholar 

• Schweighauser M, Shi Y, Tarutani A, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature. 2020;585:464–9. Using cryo-electron microscopy, the authors observed different structures of alpha-synuclein filaments in MSA and between MSA and DLB patients. This suggests that different alpha-synuclein strains could be related to distinct synucleinopathies

ADS  CAS  PubMed  PubMed Central  Google Scholar 

•• Wenning GK, Stankovic I, Vignatelli L, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Movement Disorders. 2022;37:1131–48. This revision of diagnostic criteria of MSA aims to improve diagnosis accuracy at earlier stages of the disease and describes a new category of clinically established MSA that requires the presence of brain imaging features

PubMed  PubMed Central  Google Scholar 

Miki Y, Foti SC, Asi YT, Tsushima E, Quinn N, Ling H, Holton JL. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain. 2019;142:2813–27.

PubMed  Google Scholar 

Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW. When DLB, PD, and PSP masquerade as MSA. Neurology. 2015;85:404–12.

CAS  PubMed  PubMed Central  Google Scholar 

Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord. 2009;24:2272–6.

PubMed  Google Scholar 

• Virameteekul S, Revesz T, Jaunmuktane Z, Warner TT, De Pablo-Fernández E. Pathological validation of the MDS criteria for the diagnosis of multiple system atrophy. Movement Disorders. 2023;38:444–52. This article provides evidence of enhanced diagnostic performances of the new diagnostic criteria of MSA and excellent accuracy of the new category of clinically established MSA, even at the early stages of the disease

PubMed  Google Scholar 

Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391–402.

PubMed  Google Scholar 

•• Krismer F, Palma J-A, Calandra-Buonaura G, et al. The unified multiple system atrophy rating scale: status, critique, and recommendations. Movement Disorders. 2022;37:2336–41. This review article describes the main limitation of the UMSARS and provides a roadmap to a revised version of the scale. The authors announced the creation of a task force of experts and the preparatory steps for an exhaustive documentation to provide a more comprehensive and patient-centered scale

PubMed  PubMed Central  Google Scholar 

Krismer F, Seppi K, Jönsson L, et al. Sensitivity to change and patient-centricity of the unified multiple system atrophy rating scale items: a data-driven analysis. Movement Disorders. 2022;37:1425–31.

PubMed  PubMed Central  Google Scholar 

Potashman M, Brady L, Durham S, et al (2023) Psychometric validation of a modified united multiple system atrophy rating scale (S43.002). In: Wednesday, April 26. Lippincott Williams & Wilkins, p 1958

Potashman M, Huang I, Durham S, et al. Patient concept elicitation interviews: insights into multiple system atrophy (MSA) patient experiences and relevance of a modified united multiple system atrophy rating scale (P8-9.003). In: Tuesday, April 25. Lippincott Williams & Wilkins; 2023. p. 2057.

Google Scholar 

Palma J-A, Vernetti PM, Perez MA, et al. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clin Auton Res. 2021;31:157–64.

PubMed  PubMed Central  Google Scholar 

Foubert-Samier A, Pavy-Le Traon A, Saulnier T, Le-Goff M, Fabbri M, Helmer C, Rascol O, Proust-Lima C, Meissner WG. An item response theory analysis of the unified multiple system atrophy rating scale. Parkinsonism & Related Disorders. 2022;94:40–4.

Google Scholar 

Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG. Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis. 2020;139:104813.

PubMed  Google Scholar 

Saulnier T, Philipps V, Meissner WG, Rascol O, Pavy-Le Traon A, Foubert-Samier A, Proust-Lima C. Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout. Methods. 2022;203:142–51.

CAS  PubMed  Google Scholar 

Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP-L, Payoux P, Meissner WG, Rascol O. MRI supervised and unsupervised classification of Parkinson’s disease and multiple system atrophy. Mov Disord. 2018;33:600–8.

PubMed  Google Scholar 

Chougar L, Faouzi J, Pyatigorskaya N, et al. Automated categorization of Parkinsonian syndromes using magnetic resonance imaging in a clinical setting. Movement Disorders. 2021;36:460–70.

CAS  PubMed  Google Scholar 

• Smith R, Capotosti F, Schain M, et al. The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun. 2023;14:6750. This article shows a promising perspective for the use of an alpha-synuclein PET tracer to enhance diagnostic performances. The authors presented a specific biding to strategic brain regions related to MSA pathology and the ability of the tracer to distinguish between MSA patients and healthy controls or other synucleinopathies

ADS  CAS  PubMed  PubMed Central  Google Scholar 

• Poggiolini I, Gupta V, Lawton M, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2022;145:584–95. In this article, the authors explored the ability of seed amplification assay to distinguish between synucleinopathies and predict disease conversion of REM-sleep behavior disorder. This highlights the potential use of this method to detect synucleinopathy at prodromal stages

PubMed  Google Scholar 

Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140:49–62.

CAS  PubMed  PubMed Central  Google Scholar 

Chelban V, Nikram E, Perez-Soriano A, et al. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain. 2022;145:4398–408.

PubMed  PubMed Central  Google Scholar 

Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol. 2020;88:503–12.

CAS  PubMed  PubMed Central  Google Scholar 

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington’s disease. New England Journal of Medicine. 2019;380:2307–16.

CAS  PubMed  Google Scholar 

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials - Wave Life Sciences. https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-provides-update-phase-1b2a-precision-hd. Accessed 17 May 2023

Alarcón-Arís D, Recasens A, Galofré M, et al. Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s disease. Mol Ther. 2018;26:550–67.

PubMed  Google Scholar 

Uehara T, Choong C-J, Nakamori M, et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease. Sci Rep. 2019;9:7567.

ADS  PubMed  PubMed Central  Google Scholar 

Miquel-Rio L, Alarcón-Arís D, Torres-López M, et al. Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy. Transl Psychiatry. 2022;12:79.

CAS  PubMed  PubMed Central  Google Scholar 

Kallab M, Herrera-Vaquero M, Johannesson M, Eriksson F, Sigvardson J, Poewe W, Wenning GK, Nordström E, Stefanova N. Region-specific effects of immunotherapy with antibodies targeting α-synuclein in a transgenic model of synucleinopathy. Front Neurosci. 2018;12:452.

PubMed  PubMed Central  Google Scholar 

Schofield DJ, Irving L, Calo L, et al. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol Dis. 2019;132:104582.

CAS  PubMed  Google Scholar 

Knecht L, Folke J, Dodel R, Ross JA, Albus A. Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective. Neurotherapeutics. 2022;19:1489–502.

CAS  PubMed  PubMed Central  Google Scholar 

Schneeberger A, Mandler M, Mattner F, Schmidt W. AFFITOME® technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin. 2010;6:948–52.

CAS  PubMed  Google Scholar 

Levin J, Maaß S, Schuberth M, et al. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2019;18:724–35.

CAS  PubMed  Google Scholar 

Finkelstein DI, Billings JL, Adlard PA, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease. Acta Neuropathol Commun. 2017;5:53.

PubMed  PubMed Central